Zhuo ZL, Xian HP, Sun YJ, Long Y, Liu C, Liang B, Zhao XT. Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1. World J Gastroenterol 2022; 28(34): 4973-4992 [PMID: 36160641 DOI: 10.3748/wjg.v28.i34.4973]
Corresponding Author of This Article
Xiao-Tao Zhao, MD, Director, Department of Clinical Laboratory, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. zhaoxt@bjmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 14, 2022; 28(34): 4973-4992 Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4973
Long noncoding RNA ZNFX1-AS1 promotes the invasion and proliferation of gastric cancer cells by regulating LIN28 and CAPR1N1
Zhong-Ling Zhuo, Hai-Peng Xian, Yu-Jing Sun, Yan Long, Chang Liu, Bin Liang, Xiao-Tao Zhao
Zhong-Ling Zhuo, Hai-Peng Xian, Yan Long, Chang Liu, Xiao-Tao Zhao, Department of Clinical Laboratory, Peking University People’s Hospital, Beijing 100044, China
Zhong-Ling Zhuo, The Key Laboratory of Geriatrics, Peking University Fifth School of Clinical Medicine, Beijing 100730, China
Yu-Jing Sun, Department of Clinical Laboratory, Peking University International Hospital, Beijing 100044, China
Bin Liang, Department of Gastrointestinal Surgery, Peking University People’s Hospital, Beijing 100044, China
Author contributions: Zhuo ZL analyzed the experimental data and completed the draft of the manuscript; Xian HP completed all of the experiments; Sun YJ, Long Y, and Liu C collected all of the clinical data; Liang B and Zhao XT are responsible for designing the work and for final approval of the version to be published.
Institutional review board statement: This study was approved by the Research Ethics Committee of Peking University People’s Hospital. Patient data and samples were treated according to the ethical and legal criteria adopted in the 2013 Declaration of Helsinki. Written informed consent for ethical approval and patient consent was obtained from all participants.
Institutional animal care and use committee statement: This study was approved by the Peking University People’s Hospital Animal Use Protocol & Ethic Review.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Tao Zhao, MD, Director, Department of Clinical Laboratory, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. zhaoxt@bjmu.edu.cn
Received: August 2, 2021 Peer-review started: August 2, 2021 First decision: October 2, 2021 Revised: October 29, 2021 Accepted: August 23, 2022 Article in press: August 23, 2022 Published online: September 14, 2022 Processing time: 401 Days and 6.4 Hours
ARTICLE HIGHLIGHTS
Research background
Long noncoding RNA (lncRNA) ZNFX1-AS1 (ZFAS1) is a newly discovered lncRNA, but its diagnostic value in gastric cancer is unclear.
Research motivation
We investigated the biological effects of ZFAS1 on the survival, proliferation, and migration of gastric cancer cells.
Research objectives
This study aimed to investigate the potential role of ZFAS1 in gastric cancer and to evaluate the clinical significance of ZFAS1 as a biomarker for gastric cancer screening.
Research methods
RNA extraction, quantitative realtime polymerase chain reaction, lncRNA silencing and overexpression, MTT assay, transwell migration assay, Colony formation assay, protein extraction, immunosorbent assay, and in vivo tumor formation assay were performed in this study.
Research results
ZFAS1 amplification was correlated with poor prognosis in gastric cancer. ZFAS1 knockdown inhibited the viability, migration, and proliferation of gastric cancer cells. ZFAS1 overexpression enhanced the viability, migration, and proliferation of gastric cancer cells. LIN28 and CAPRIN1 were the key downstream mediators of ZFAS1 in gastric cancer cells. ZFAS1 was associated with the tumorigenesis of gastric cancer cells in vivo.
Research conclusions
LncRNA ZFAS1 is a potential biomarker for gastric cancer.
Research perspectives
ZFAS1 plays an oncogenic role in gastric cancer and can be used as a potential diagnostic biomarker and a new therapeutic target for gastric cancer.
